Lysophosphatidic Acid Induces MDA-MB-231 Breast Cancer Cells Migration through Activation of PI3K/PAK1/ERK Signaling
Authors:
Open Access
- 30 December 2010
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 5 (12) , e15940
Abstract
Enhanced motility of cancer cells is a critical step in promoting tumor metastasis. Lysophosphatidic acid (LPA), representing the major mitogenic activity in serum, stimulates migration in various types of cancer cells. However, the underlying signaling mechanisms for LPA-induced motility of cancer cells remain to be elucidated. In this study, we found that LPA dose-dependently stimulated migration of MDA-MB-231 breast cancer cells, with 10 µM being the most effective. LPA also increased ERK activity and the MEK inhibitor U0126 could block LPA-induced ERK activity and cell migration. In addition, LPA induced PAK1 activation while ERK activation and cell migration were inhibited by ectopic expression of an inactive mutant form of PAK1 in MDA-MB-231 cells. Furthermore, LPA increased PI3K activity, and the PI3K inhibitor LY294002 inhibited both LPA-induced PAK1/ERK activation and cell migration. Moreover, in the breast cancer cell, LPA treatment resulted in remarkable production of reactive oxygen species (ROS), while LPA-induced ROS generation, PI3K/PAK1/ERK activation and cell migration could be inhibited by N-acetyl-L-Cysteine, a scavenger of ROS. Taken together, this study identifies a PI3K/PAK1/ERK signaling pathway for LPA-stimulated breast cancer cell migration. These data also suggest that ROS generation plays an essential role in the activation of LPA-stimulated PI3K/PAK1/ERK signaling and breast cancer cell migration. These findings may provide a basis for designing future therapeutic strategy for blocking breast cancer metastasis.Keywords
This publication has 58 references indexed in Scilit:
- Lysophosphatidic acid production and action: critical new players in breast cancer initiation and progressionBritish Journal of Cancer, 2010
- PAK signaling in oncogenesisOncogene, 2009
- Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer modelsProceedings of the National Academy of Sciences, 2009
- Trihydrophobin 1 Interacts with PAK1 and Regulates ERK/MAPK Activation and Cell MigrationJournal of Biological Chemistry, 2009
- Breast cancer risk in elderly women with systemic autoimmune rheumatic diseases: a population-based case–control studyBritish Journal of Cancer, 2009
- Lysophosphatidic acid‐induced ERK activation and chemotaxis in MC3T3‐E1 preosteoblasts are independent of EGF receptor transactivationJournal of Cellular Physiology, 2009
- PAK1-mediated activation of ERK1/2 regulates lamellipodial dynamicsJournal of Cell Science, 2008
- MEK1 activation by PAK: A novel mechanismCellular Signalling, 2007
- The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastasesProceedings of the National Academy of Sciences, 2006
- The emerging role of lysophosphatidic acid in cancerNature Reviews Cancer, 2003